Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding
The advantage of apixaban was consistent across a variety of subgroups and confirms earlier observations.
Related Articles
Simple Sitting-Rising Test Linked to Natural and CV Mortality
The test of nonaerobic functioning may raise awareness that people need to work on balance and flexibility as they age.
Underexpanded Acurate Valves Come With Higher Stroke Risk, Study Confirms
Though the Acurate neo and neo2 valves are no longer available, there are lessons here for other self-expanding TAVI platforms.
‘Sobering’ Adverse Event Rate With Evoque Seen in Real-world Use
Responding to MAUDE data, some have safety concerns but others aren’t surprised to see more events in higher-risk patients.
Acute Coronary Care in Ethiopia
Mamas Mamas talks to Tesfaye Telila about the landscape of acute coronary care in Ethiopa, where just a few dozen cardiologists contend with a population…
FDA Approves Triple Therapy Polypill for High Blood Pressure
The combination will be available in several doses and is also approved as a first-line option for patients with hypertension.
Studying the Clinical Impact of Restoring Native Flow with Biomimetic DurAVR® THV
Martin B. Leon, MD Columbia University New York, NY Tsuyoshi Kaneko, MD Washington University St. Louis, MO Brian Lindman, MD Vanderbilt University Nashville, TN Jeffrey…
Valve Thrombosis in TTVR Not Uncommon: Meta-analysis
Most cases are subclinical, but given the newness of the therapy, it’s necessary to keep tabs on the issue going forward.
Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels
Primary Investigator, Bernardo Cortese MD, proudly announces the successful completion of patient enrollment in the TRANSFORM II randomized controlled trial (RCT). This pivotal study aims…